Gastric Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 15, 2004; 10(14): 2010-2013
Published online Jul 15, 2004. doi: 10.3748/wjg.v10.i14.2010
Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor
Hong Gao, Ji-Yao Wang, Xi-Zhong Shen, Yong-Hui Deng, Wei Zhang
Hong Gao, Ji-Yao Wang, Xi-Zhong Shen, Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Yong-Hui Deng, Department of Macromolecular Sciences, Fudan University, Shanghai 200032, China
Wei Zhang, Department of Gastroenterology, Huadong Hospital, Shanghai 200040, China
Author contributions: All authors contributed equally to the work.
Supported by the National High Technology Research and Development Program of China 863 Program, No. 2001AA218011
Correspondence to: Dr. Xi-Zhong Shen, Associate Chief of Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. shenxz@zshopital.net
Telephone: +86-21-64041990-2070 Fax: +86-21-34160980
Received: February 2, 2004
Revised: February 11, 2004
Accepted: February 21, 2004
Published online: July 15, 2004
Abstract

AIM: To evaluate the effect of aclacinomycin A-loaded magnetic polybutylcyanoacrylate nanoparticles on gastric tumor growth in vivo and in vitro.

METHODS: Magnetic polybutylcyanoacrylate (PBCA) nanospheres encapsulated with aclacinomycin A (MPNS-ACM) were prepared by interfacial polymerization. Particle size, shape and drug content were examined. Female BABL/c nude mice were implanted with MKN-45 gastric carcinoma tissues subcutaneously to establish human gastric carcinoma model. The mice were randomly divided into 5 groups of 6 each: ACM group (8 mg/kg bm); group of high dosage of MPNS-ACM (8 mg/kg bm); group of low dosage of MPNS-ACM (1.6 mg/kg bm); group of magnetic PBCA nanosphere (MPNS) and control group (normal saline). Magnets (2.5 T) were implanted into the tumor masses in all of the mice one day before the therapy. Above-mentioned drugs were administered intravenously to the mice of every group on the first day and sixth day. When the mice were sacrificed, tumor weight was measured, and the assay of granulocyte- macrophage colony forming-unit (CFU-GM) was performed on semi-solid culture. White blood cell, alanine aminotransferase and creatine were examined. 3-[4-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was used to examine the viability of MKN-45 cells after incubation with different concentrations of ACM, MPNS and MPNS-ACM suspension respectively for 48 h.

RESULTS: Content of ACM in MPNS-ACM was 12.0% and the average diameter of the particles was 210 nm. The inhibitory rates of ACM (8 mg/kg bm), high dosage of MPNS-ACM (8 mg/kg bm), low dosage of MPNS-ACM (1.6 mg/kg bm) and MPNS on human gastric carcinoma in nude mice were 22.63%, 52.55%, 30.66% and 10.22%, respectively. There was a significant decrease in the number of CFU-GM of bone marrow in ACM group compared with control group, whereas no obvious change was observed in that of the nanosphere groups. The values of 50% inhibition concentration (IC50) of ACM, MPNS and MPNS-ACM were 0.09, 97.78 and 1.07 μg/mL, respectively.

CONCLUSION: The tumor inhibitory rate of MPNS-ACM was much higher than that of ACM under magnetic field and the inhibition on bone marrow was alleviated significantly compared with ACM group.

Keywords: $[Keywords]